US 2022/0033429 A1 · MITHRAMYCIN DERIVATIVES HAVING INCREASED SELECTIVITY AND ANTI-CANCER ACTIVITY

Abstract

Mithramycin (MTM) short side chain ketone (SK) derivatives and MTM short side chain diketone (SDK) derivatives are provided. The MTM SK and MTM SDK derivatives are useful for treatment of cancer or neuro-diseases associated with an aberrant erythroblast transformation-specific transcription factor. Unique MTM SK and MTM SDK derivatives have increased selectively toward ETS transcription factor.

Claims15

Dependent claims

A mithramycin (MTM) short side chain ketone (SK) derivatives and MTM short side chain diketone (SDK) derivative having the following formula:

MTM-SK/SDK-R2
or a pharmaceutically acceptable salt thereof, wherein R2 can be an amino acid derivative or a dipeptide derivative.

Dependencies are inferred from the claim text.

Facts

Application

17/278,070Filed 20 Sep 2019

Priority

21 Sep 2018

Published

3 Feb 2022

Term ends

Not estimatedThe source records don’t support an estimate.

Classification6 codes

A61P 35/00
Antineoplastic agents
C07H 15/24
Carbocyclic rings: condensed ring systems having three or more rings
A61K 31/704
Attached to a carbocyclic compound, e.g. phloridzin: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin,…
A61P
Therapeutic uses of medicines

Mithramycin derivatives having increased selectivity and anti-cancer activity

Life of this patent

Mithramycin derivatives having increased selectivity and anti-cancer activity

Life of this patent

Abstract

Claims15